# A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

> **NCT05763121** · PHASE3 · TERMINATED · sponsor: **Areteia Therapeutics** · enrollment: 1061 (actual)

## Conditions studied

- Eosinophilic Asthma
- Asthma; Eosinophilic
- Asthma

## Interventions

- **DRUG:** Dexpramipexole Dihydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05763121
- **Lead sponsor:** Areteia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-30
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 1061 (ACTUAL)
- **Why stopped:** Program stopped due to the benefit risk profile no longer supports further development in the intended patient population.
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763121, "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05763121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*